Hims & Hers Health (NYSE:HIMS) Downgraded by Wall Street Zen to "Hold"

Wall Street Zen cut shares of Hims & Hers Health (NYSE:HIMS - Free Report) from a buy rating to a hold rating in a research note published on Saturday morning.

Several other brokerages have also recently issued reports on HIMS. Citigroup restated a "sell" rating and issued a $30.00 price target (up previously from $25.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. UBS Group reissued a "mixed" rating on shares of Hims & Hers Health in a report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $38.00.

Hims & Hers Health Price Performance

Shares of HIMS stock traded down $1.71 during trading hours on Friday, reaching $55.15. 38,232,363 shares of the stock were exchanged, compared to its average volume of 20,874,016. The business's fifty day moving average is $43.29 and its two-hundred day moving average is $37.67. The firm has a market capitalization of $12.35 billion, a P/E ratio of 125.35 and a beta of 2.09. Hims & Hers Health has a 12-month low of $13.47 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm's revenue was up 110.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.05 earnings per share. As a group, equities research analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 5,100 shares of Hims & Hers Health stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $56.00, for a total transaction of $285,600.00. Following the completion of the transaction, the insider now directly owns 256,580 shares in the company, valued at $14,368,480. The trade was a 1.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $60.22, for a total value of $697,407.82. Following the transaction, the chief financial officer now owns 113,816 shares in the company, valued at $6,853,999.52. This trade represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 622,467 shares of company stock valued at $25,513,488. 13.71% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

Hedge funds have recently made changes to their positions in the company. Blume Capital Management Inc. increased its stake in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the 1st quarter worth $30,000. Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares during the last quarter. Summit Securities Group LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $38,000. Finally, UMB Bank n.a. raised its stake in shares of Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after purchasing an additional 933 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.